BRUSSELS, BELGIUM, 9 May 2023 — The European Thrombosis and Haemostasis Alliance (ETHA), initiated and supported by the International Society on Thrombosis and Haemostasis (ISTH), is pleased to announce the election of Mettine Bos, Ph.D., as vice chair of the organisation for a term of two years.
Bos is an Assistant Professor at the Leiden University Medical Center in The Netherlands. As the Vice Chair of ETHA, Bos will work closely with the Chair Ingrid Pabinger-Fasching, Ph.D., and Alliance members to further the mission to bring awareness to thrombosis and hemostasis as a critical global patient safety issue.
Formed in 2018, the ETHA was created to advocate for better awareness and prioritisation of thrombosis and hemostasis in European Union (EU) patient safety and research programmes. The ETHA, comprised of 26 related national societies, has a united focus to work with the public and decision-makers to share expertise in clotting and bleeding disorders, elevate patient-centric policies and promote improved outcomes in the EU.
"My appointment as the vice chair of ETHA is a great opportunity to collaborate with esteemed experts in the thrombosis and hemostasis community to advance research and prevention efforts across Europe," said Bos. "Building upon the accomplishments of the Alliance is an honor, and I am confident that by working together we will continue to make significant strides towards ETHA's mission of improving patient care and advancing research. I am eager to work alongside our chair and colleagues to make a meaningful impact on the lives of patients and their families."
Bos completed her graduate work at the Department of Plasma Proteins at Sanquin Research (Amsterdam, The Netherlands) and postdoctoral fellowship in the Camire Lab at the Children’s Hospital of Philadelphia (U.S.). As Principal Investigator at the Einthoven Laboratory for Vascular and Regenerative Medicine in Leiden, The Netherlands, her research focuses on structure-function aspects of blood coagulation proteins, with the overall goal of engineering innovative therapeutic proteins or identifying novel targets for the treatment of either bleeding or thrombosis. Bos previously developed a novel procoagulant protein that is currently in clinical development as a reversal agent to restore hemostasis in patients taking factor Xa inhibitors.
"We are delighted to announce that Bos, an accomplished researcher and expert in the field of thrombosis and hemostasis, has joined ETHA as the vice chair," said Chair Pabinger-Fasching. "With her extensive background in both basic and translational research, she is the ideal candidate to help guide ETHA's efforts in raising awareness, promoting research, and improving patient care across Europe. Bos has an impressive track record of leadership and has held key positions, including serving as the president of the Dutch Society for Thrombosis and Haemostasis. We look forward to working with Bos and leveraging her expertise to advance ETHA's mission."
To learn more about the ETHA, visit www.etha.eu.
About European Thrombosis and Haemostasis Alliance (ETHA)
Initiated by the International Society on Thrombosis and Haemostasis (ISTH), the European Thrombosis and Haemostasis Alliance (ETHA) is made up of European national societies representing those working in the field of thrombotic and bleeding disorders. ETHA has come together to give the European thrombosis and hemostasis community an allied voice and provide input to EU health and patient safety strategies; make recommendations on EU research programme funding and encourage sharing and adoption of best practices in the treatment and prevention of thrombotic and bleeding disorders across Member States. For a full list of member organizations and to learn more about the alliance, visit www.etha.eu.
About the International Society on Thrombosis and Haemostasis (ISTH)
Founded in 1969, the ISTH is the leading worldwide medical and scientific professional Society dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis. ISTH’s international professional membership includes more than 7,000 clinicians, researchers, and educators working together to improve the lives of patients in more than 124 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and congresses, peer-reviewed publications, expert committees, and the annual World Thrombosis Day campaign on October 13. Visit ISTH online at www.isth.org.
###
For further information, please contact Louise St. Germain at Louise_StGermain@isth.org.
Comments